Business
-
Vectura is not saying which international pharmaceutical company’s US division has entered into a “collaboration, development, and license agreement” for the VR315 dry powder inhaler. VR315 is a fixed dose combination therapy for asthma and… Read more . . .
-
SkyePharma has announced that it has entered into a development, license, and marketing agreement for its Flutiform fluticasone and formoterol combination MDI with Sanofi in Mexico, Central America and South America. Sanofi will submit marketing… Read more . . .
-
According to the US Health and Human Service Department’s Agency for Healthcare Research and Quality (AHRQ), the average annual cost of prescription drugs to treat a child with asthma in the US rose from $349… Read more . . .
-
Armstrong Pharmaceuticals is advising customers to stockpile its Primatene Mist epinephrine MDI before the FDA ban on CFC formulations takes effect on December 31, 2011. The company says that it is “actively finalizing its internal… Read more . . .
-
A small portion of Gilead’s 11% increase in revenue for the second quarter of 2011 compared to the same quarter in 2010 is attributable to a 105% increase in the US sales of Cayston astreonam… Read more . . .
-
Existing shareholders have agreed to purchase additional Aradigm Corporation common stock for a total of $4.75 million. The three shareholders will pay $0.19 per share for 25 million shares. The net proceeds for Aradigm after… Read more . . .
-
Particle engineering company Prosonix has secured £11.4M from a group of investors led by French venture company Ventech. Other investors involved in this round of financing include Entrepreneurs Fund, Quest for Growth, and Solon Ventures,… Read more . . .
-
Gerresheimer will spend €12m to add approximately 5,000 sq. meters to the plastics production area at its manufacturing facility in Horsovsky Tyn, Czech Republic. The plant produces medical plastic devices, including insulin pens and inhalers.… Read more . . .
-
According to news reports, Pfizer has reversed its position on the closure of its R&D facility at Sandwich, UK, saving 350 jobs. The company’s inhalation R&D group has operated out of Sandwich and had been… Read more . . .
-
Pearl Therapeutics is advancing its PT003 combination inhaler for COPD, and the products individual components, into a new series of Phase 2 trials in patients with moderate-to-severe COPD. The individual compounds are PT001, glycopyrrolate, and… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden